Neurimmune and TVM Capital Life Science have partnered to create and fund a single-asset biotech focused on amyotrophic lateral sclerosis.

Chinese researchers are publishing more than three times as many research papers on cancer topics than they were a decade ago.

After a torrid year that has seen multiple deaths in testing, FDA- and self-imposed study halts and its shares tanking, Juno last night held up to the light…

AbbVie has struck five-year cancer research pacts with Johns Hopkins University School of Medicine and Northwestern University's Lurie Cancer Center.

After passing on an option to buy Acetylon in the summer, Celgene has come back with a deal for a slimmed-down version of the biotech.

British biotech ReNeuron has posted generally encouraging midstage data which showed their stem cell therapy could help certain stroke patients move their arms…

Agios Pharmaceuticals has moved closer to starting a pivotal clinical trial of one of its wholly owned treatments for pyruvate kinase deficiency.

Despite looking to have taken a big step back from cell therapy work this year, Novartis hopes to be first to market a new CAR-T med as it plans to file early…

Biotech